Breaking Finance News

Needham disclosed Livanova Plc (NDAQ:LIVN), hiking its price target to $83.00 today

Boasting a price of $68.38, Livanova Plc (NDAQ:LIVN) traded 4.53% higher on the day. The last closing price is up 18.48% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the same period. LIVN has recorded a 50-day average of $62.35 and a two hundred day average of $57.45. Trade Volume was up over the average, with 808,601 shares of LIVN changing hands over the typical 527,142

In a report released on Friday September 15, 2017 Needham increased the stock price target of Livanova Plc (NDAQ:LIVN) to $83.00 stating a potential upside of 0.21%.

On 9/12/2017, Piper Jaffray released a statement on Livanova Plc (NDAQ:LIVN) bumped up the target price from $0.00 to $75.00 that suggested an upside of 0.15%.

Recent Performance Chart

Livanova Plc (NDAQ:LIVN)

Livanova Plc has price-earnings ratio of 121.55 with a one year low of $40.83 and a one year high of $68.15 and has a total market value of $0.

Brief Synopsis About Livanova Plc (NDAQ:LIVN)

LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company's segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products. Cardiac Surgery products include oxygenators, heart-lung machines, autotransfusion, mechanical heart valves and tissue heart valves. The Cardiac Rhythm Management segment is engaged in the development, manufacturing and marketing of products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Cardiac Rhythm Management products include high-voltage defibrillators Cardiac Resynchronization Therapy device (CRT-D) and low-voltage pacemakers. The Neuromodulation segment is engaged in the design, development and marketing of neuromodulation therapy for the treatment of drug-resistant epilepsy and treatment resistant depression.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.